Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: A randomized controlled trial

Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial

(2022) J Ruwaard et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification

(2021) Johannes J.M. Rood et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases

(2021) Silje Watterdal Syversen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

(2021) Silje Watterdal Syversen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis

(2020) Andreas Kerschbaumer et al.   ANNALS OF THE RHEUMATIC DISEASES

Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

(2020) Celia A. J. Michielsens et al.   Trials

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

(2020) Laure Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab, and TNFi biologics in RA: results from the nationwide SWEDISH register: reply

(2019) Thomas Frisell et al.   RHEUMATOLOGY

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis

(2019) MJ l’ Ami et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)

(2019) Ana-Maria Orbai et al.   RHEUMATOLOGY

Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting

(2018) Pablo J. Maid et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis

(2018) F Siljehult et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

(2017) Robert J. Moots et al.   PLoS One

Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review

(2016) Laura Martelli et al.   JOURNAL OF GASTROENTEROLOGY

Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis

(2015) David Ternant et al.   CLINICAL PHARMACOKINETICS

Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis

(2015) Meghna Jani et al.   Arthritis & Rheumatology

Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

(2014) E L Kneepkens et al.   ANNALS OF THE RHEUMATIC DISEASES

Key findings towards optimising adalimumab treatment: the concentration–effect curve

(2013) Mieke F Pouw et al.   ANNALS OF THE RHEUMATIC DISEASES

The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis

(2013) Bart J. F. van den Bemt et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

(2013) Casper Steenholdt et al.   GUT

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

(2012) Aatke van der Maas et al.   BMC MUSCULOSKELETAL DISORDERS

ACR/EULAR 2010 rheumatoid arthritis classification criteria

(2012) J. Kay et al.   RHEUMATOLOGY

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?

(2011) Pal Miheller et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

(2009) Merete Lund Hetland et al.   ARTHRITIS AND RHEUMATISM

The Disease Activity Score and the EULAR Response Criteria

(2009) Jaap Fransen et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA